Simultaneous high-performance liquid chromatographic determination of carbamazepine and its principal metabolites in human plasma and urine.
A rapid high-performance liquid chromatographic method is described for the simultaneous determination of carbamazepine and the 10,11-epoxide, 10,11-dihydroxy, and 2-hydroxy metabolites of carbamazepine. The chromatographic system involves the use of a 18C-microsorb, reversed-phase column with acetonitrile/water (28:72) as the mobile phase. Detection and quantitation are monitored by ultraviolet absorption at 212 nm. The compounds are extracted from 250 microliters of plasma or from 100 microliters urine with methyl-t-butyl ether and 0.1 M sodium hydroxide; 2-methylcarbamazepine is added as internal standard. If phenytoin and/or phenobarbital are present in plasma or urine samples, it is necessary to use 1.0 M sodium hydroxide. The limits of quantitation for carbamazepine and its metabolites are 10 ng/ml.
Chelberg
R D
RD
Neurology Service, Veterans Administration West Los Angeles Medical Center, California.
Gunawan
S
S
Treiman
D M
DM
D001711:Biotransformation; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000032:analysis / Q000097:blood / Q000378:metabolism* / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D006801:Humans
D002220:Carbamazepine; C004822:10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide; C056205:2-hydroxycarbamazepine; C012227:carbamazepine epoxide